Tesaro and China's Zai Lab link up on cancer candidate niraparib

30 September 2016

Oncology-focussed US biotech firm Tesaro (Nasdaq: TSRO) and China-based Zai Lab have announced a collaboration to develop and commercialize niraparib for patients in China, with the further potential to advance two immuno-oncology programs outside of the Asian country.

Within this collaboration, Tesaro has granted to Zai Lab an exclusive license for the development of niraparib specifically for the Chinese market, which includes an option for the Boston-based company to participate in the commercialization of the drug in greater China.

The companies will establish a joint steering committee to review and oversee all development and commercialization plans. In addition, Tesaro has the option to license two novel, discovery-stage immuno-oncology programs from Zai Lab.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK